Transactions
18
Insider / REPLIGEN CORP
Hunt Anthony
Director at REPLIGEN CORP
- Company
- REPLIGEN CORP
- Ticker
- RGEN
- First filing on record
- November 13, 2025
- Latest trade on record
- March 2, 2026
- SEC filings
- EDGAR ↗
Hunt Anthony, Director at REPLIGEN CORP, has disclosed 18 transactions in RGEN since November 13, 2025: 0 purchases (0 open-market buys) and 13 sales, worth about $9.2M at the reported prices. The latest was filed March 3, 2026, 1 day after the trade.
Open-market buys
0
Sales
13
Avg. disclosure lag
1.2d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Hunt Anthony made no purchases and 13 sales worth $8.3M, plus 5 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Hunt Anthony has traded 1 stock on record; the largest by dollars is RGEN.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 12 | 45,000 | $7.0M |
| M | Option exercise or conversion | 4 | 55,904 | $947K |
| F | Shares withheld for tax | 1 | 9,897 | $1.2M |
| J | Other acquisition or disposal | 1 | 2,000 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 1 · $1.2M |
| 2025 | 17 | 0 | 12 · $7.0M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| RGEN | Sell F | March 2, 2026 | March 3, 2026 | 1d | 9,897 | $125 | $1.2M | Form 4 ↗ | ||
| RGEN | Other J | December 4, 2025 | December 8, 2025 | 4d | 2,000 | — | — | Form 4 ↗ | ||
| RGEN | Option / conversion M | November 13, 2025 | November 14, 2025 | 1d | 2,952 | — | — | derivative | Form 4 ↗ | |
| RGEN | Option / conversion M | November 13, 2025 | November 14, 2025 | 1d | 2,952 | $34 | $100K | Form 4 ↗ | ||
| RGEN | Sell S | November 13, 2025 | November 14, 2025 | 1d | 1,956 | $157 | $307K | Form 4 ↗ | ||
| RGEN | Sell S | November 13, 2025 | November 14, 2025 | 1d | 5,737 | $156 | $896K | Form 4 ↗ | ||
| RGEN | Sell S | November 13, 2025 | November 14, 2025 | 1d | 3,000 | $155 | $466K | Form 4 ↗ | ||
| RGEN | Sell S | November 13, 2025 | November 14, 2025 | 1d | 2,500 | $154 | $386K | Form 4 ↗ | ||
| RGEN | Sell S | November 13, 2025 | November 14, 2025 | 1d | 2,923 | $153 | $448K | Form 4 ↗ | ||
| RGEN | Sell S | November 13, 2025 | November 14, 2025 | 1d | 2,100 | $152 | $320K | Form 4 ↗ | ||
| RGEN | Sell S | November 13, 2025 | November 14, 2025 | 1d | 1,784 | $151 | $269K | Form 4 ↗ | ||
| RGEN | Option / conversion M | November 12, 2025 | November 13, 2025 | 1d | 25,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| RGEN | Sell S | November 12, 2025 | November 13, 2025 | 1d | 464 | $159 | $74K | 10b5-1 plan | Form 4 ↗ | |
| RGEN | Sell S | November 12, 2025 | November 13, 2025 | 1d | 11,096 | $158 | $1.8M | 10b5-1 plan | Form 4 ↗ | |
| RGEN | Sell S | November 12, 2025 | November 13, 2025 | 1d | 4,959 | $157 | $777K | 10b5-1 plan | Form 4 ↗ | |
| RGEN | Sell S | November 12, 2025 | November 13, 2025 | 1d | 4,740 | $156 | $739K | 10b5-1 plan | Form 4 ↗ | |
| RGEN | Sell S | November 12, 2025 | November 13, 2025 | 1d | 3,741 | $155 | $580K | 10b5-1 plan | Form 4 ↗ | |
| RGEN | Option / conversion M | November 12, 2025 | November 13, 2025 | 1d | 25,000 | $34 | $847K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| March 3, 2026 | Form 4 | 0001193125-26-087591 | 1 | published | EDGAR ↗ |
| December 8, 2025 | Form 4 | 0001193125-25-311290 | 1 | published | EDGAR ↗ |
| November 14, 2025 | Form 4 | 0001193125-25-283092 | 9 | published | EDGAR ↗ |
| November 13, 2025 | Form 4 | 0001193125-25-280266 | 7 | published | EDGAR ↗ |
Other insiders at REPLIGEN CORP
- Loeillot Olivier Chief Executive Officer 26 rows
- Bylund James Chief Operating Officer 7 rows
- Garland Jason K CFO 7 rows
- Douglass Brian Robb CHIEF PRODUCT OFFICER 6 rows
- KURIYEL RALF Senior VP, R&D 6 rows
- Madaus Martin D Interim CEO 6 rows
- MUIR GLENN P Director 6 rows
- DAWES KAREN A Director 3 rows
- BARTHELEMY NICOLAS Director 2 rows
- EGLINTON MANNER CARRIE Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: REPLIGEN CORP.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 18 | November 13, 2025 | March 3, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.